MYC Deregulation in Primary Human Cancers

Amati, 1992, Transcriptional activation by the human c-MYC oncoprotein in yeast requires interaction with MAX, Nature, 359, 423, 10.1038/359423a0

Amati, 1993, Oncogenic activity of the c-MYC protein requires dimerization with MAX, Cell, 72, 233, 10.1016/0092-8674(93)90663-B

Penn, 1990, Negative autoregulation of c-MYC transcription, EMBO J., 9, 1113, 10.1002/j.1460-2075.1990.tb08217.x

Mao, 2003, Analysis of MYC bound loci identified by CpG island arrays shows that MAX is essential for MYC-dependent repression, Curr. Biol., 13, 882, 10.1016/S0960-9822(03)00297-5

Mateyak, 1997, Phenotypes of c-MYC-deficient rat fibroblasts isolated by targeted homologous recombination, Cell Growth Differ., 8, 1039

Meyer, 2008, Reflecting on 25 years with MYC, Nat. Rev. Cancer, 8, 976, 10.1038/nrc2231

Kelly, 1983, Cell-specific regulation of the c-MYC gene by lymphocyte mitogens and platelet-derived growth factor, Cell, 35, 603, 10.1016/0092-8674(83)90092-2

Eberhardy, 2001, C-MYC mediates activation of the cad promoter via a post-RNA polymerase II recruitment mechanism, J. Biol. Chem., 276, 48562, 10.1074/jbc.M109014200

Eberhardy, 2002, MYC recruits P-TEFb to mediate the final step in the transcriptional activation of the cad promoter, J. Biol. Chem., 277, 40156, 10.1074/jbc.M207441200

Rahl, 2010, C-MYC regulates transcriptional pause release, Cell, 141, 432, 10.1016/j.cell.2010.03.030

Cowling, 2010, MYC regulation of mRNA cap methylation, Genes Cancer, 1, 576, 10.1177/1947601910378025

Cowling, 2007, The MYC transactivation domain promotes global phosphorylation of the RNA polymerase II carboxy-terminal domain independently of direct DNA binding, Mol. Cell. Biol., 27, 2059, 10.1128/MCB.01828-06

Lin, 2012, Transcriptional amplification in tumor cells with elevated c-MYC, Cell, 151, 56, 10.1016/j.cell.2012.08.026

Henriksson, 1993, Phosphorylation sites mapping in the N-terminal domain of c-MYC modulate its transforming potential, Oncogene, 8, 3199

Lutterbach, 1994, Hierarchical phosphorylation at N-terminal transformation-sensitive sites in c-MYC protein is regulated by mitogens and in mitosis, Mol. Cell. Biol., 14, 5510

Hasmall, 1997, Expression of the immediate-early genes, c-FOS, c-JUN, and c-MYC: A comparison in rats of nongenotoxic hepatocarcinogens with noncarcinogenic liver mitogens, Fundam. Appl. Toxicol., 40, 129, 10.1006/faat.1997.2371

Beroukhim, 2010, The landscape of somatic copy-number alteration across human cancers, Nature, 463, 899, 10.1038/nature08822

Ciriello, 2013, Emerging landscape of oncogenic signatures across human cancers, Nat. Genet., 45, 1127, 10.1038/ng.2762

Burrell, 2013, The causes and consequences of genetic heterogeneity in cancer evolution, Nature, 501, 338, 10.1038/nature12625

Collins, 1982, Amplification of endogenous MYC-related DNA sequences in a human myeloid leukaemia cell line, Nature, 298, 679, 10.1038/298679a0

Schwab, 1983, Amplified DNA with limited homology to MYC cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour, Nature, 305, 245, 10.1038/305245a0

Nau, 1985, L-MYC, a new MYC-related gene amplified and expressed in human small cell lung cancer, Nature, 318, 69, 10.1038/318069a0

Little, 1983, Amplification and expression of the c-MYC oncogene in human lung cancer cell lines, Nature, 306, 194, 10.1038/306194a0

Nau, 1986, Human small-cell lung cancers show amplification and expression of the N-myc gene, Proc. Natl. Acad. Sci. USA, 83, 1092, 10.1073/pnas.83.4.1092

Nakagawa, 2015, Cancer whole-genome sequencing: Present and future, Oncogene, 34, 5943, 10.1038/onc.2015.90

Tomczak, 2015, The cancer genome atlas (TCGA): An immeasurable source of knowledge, Contemp. Oncol., 19, A68

International Cancer Genome Consortium, Hudson, T.J., Anderson, W., Artez, A., Barker, A.D., Bell, C., Bernabe, R.R., Bhan, M.K., Calvo, F., and Eerola, I. (2010). International network of cancer genome projects. Nature, 464, 993–998.

Zack, 2013, Pan-cancer patterns of somatic copy number alteration, Nat. Genet., 45, 1134, 10.1038/ng.2760

Curtis, 2012, The genomic and transcriptomic architecture of 2000 breast tumours reveals novel subgroups, Nature, 486, 346, 10.1038/nature10983

Cancer Genome Atlas Network (2012). Comprehensive molecular portraits of human breast tumours. Nature, 490, 61–70.

Balko, 2014, Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets, Cancer Discov., 4, 232, 10.1158/2159-8290.CD-13-0286

Cancer Genome Atlas Research Network (2011). Integrated genomic analyses of ovarian carcinoma. Nature, 474, 609–615.

Murthy, 1990, Characterization of a solubilized malonyl-CoA-sensitive carnitine palmitoyltransferase from the mitochondrial outer membrane as a protein distinct from the malonyl-CoA-insensitive carnitine palmitoyltransferase of the inner membrane, Biochem. J., 268, 599, 10.1042/bj2680599

Cerami, 2012, The cbio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data, Cancer Discov., 2, 401, 10.1158/2159-8290.CD-12-0095

Gao, 2013, Integrative analysis of complex cancer genomics and clinical profiles using the cbioportal, Sci. Signal., 6, pl1, 10.1126/scisignal.2004088

Beltran, 2016, Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer, Nat. Medic., 22, 298, 10.1038/nm.4045

Northcott, 2012, Subgroup-specific structural variation across 1,000 medulloblastoma genomes, Nature, 488, 49, 10.1038/nature11327

Robinson, 2015, Integrative clinical genomics of advanced prostate cancer, Cell, 161, 1215, 10.1016/j.cell.2015.05.001

Guinney, 2015, The consensus molecular subtypes of colorectal cancer, Nat. Med., 21, 1350, 10.1038/nm.3967

Cancer Genome Atlas Network (2012). Comprehensive molecular characterization of human colon and rectal cancer. Nature, 487, 330–337.

Seshagiri, 2012, Recurrent R-spondin fusions in colon cancer, Nature, 488, 660, 10.1038/nature11282

He, 1998, Identification of c-MYC as a target of the APC pathway, Science, 281, 1509, 10.1126/science.281.5382.1509

Yada, 2004, Phosphorylation-dependent degradation of c-MYC is mediated by the F-box protein FBW7, EMBO J., 23, 2116, 10.1038/sj.emboj.7600217

Welcker, 2004, The FBW7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-MYC protein degradation, Proc. Natl. Acad. Sci. USA, 101, 9085, 10.1073/pnas.0402770101

Calonge, 1999, SMAD4/DPC4 silencing and hyperactive ras jointly disrupt transforming growth factor-β antiproliferative responses in colon cancer cells, J. Biol. Chem., 274, 33637, 10.1074/jbc.274.47.33637

Seoane, 2001, TGFβ influences Myc, Miz-1 and smad to control the CDK inhibitor p15INK4b, Nat. Cell Biol., 3, 400, 10.1038/35070086

Nagl, 2006, The c-MYC gene is a direct target of mammalian SWI/SNF-related complexes during differentiation-associated cell cycle arrest, Cancer Res., 66, 1289, 10.1158/0008-5472.CAN-05-3427

Cancer Genome Atlas Research Network (2015). The molecular taxonomy of primary prostate cancer. Cell, 163, 1011–1025.

Fraser, 2017, Genomic hallmarks of localized, non-indolent prostate cancer, Nature, 541, 359, 10.1038/nature20788

Scher, 2012, Increased survival with enzalutamide in prostate cancer after chemotherapy, N. Engl. J. Med., 367, 1187, 10.1056/NEJMoa1207506

Berruti, 2011, Abiraterone and increased survival in metastatic prostate cancer, N. Engl. J. Med., 365, 766, 10.1056/NEJMc1107198

Sutherland, 2010, Cell of origin of lung cancer, Mol. Oncol., 4, 397, 10.1016/j.molonc.2010.05.002

Cancer Genome Atlas Research Network (2012). Comprehensive genomic characterization of squamous cell lung cancers. Nature, 489, 519–525.

Imielinski, 2012, Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing, Cell, 150, 1107, 10.1016/j.cell.2012.08.029

Cancer Genome Atlas Research Network (2014). Comprehensive molecular profiling of lung adenocarcinoma. Nature, 511, 543–550.

Bailey, 2016, Genomic analyses identify molecular subtypes of pancreatic cancer, Nature, 531, 47, 10.1038/nature16965

Witkiewicz, 2015, Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets, Nat. Commun., 6, 6744, 10.1038/ncomms7744

Sato, 2013, Integrated molecular analysis of clear-cell renal cell carcinoma, Nat. Genet., 45, 860, 10.1038/ng.2699

Cancer Genome Atlas Research Network (2013). Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature, 499, 43–49.

Northcott, 2011, Medulloblastoma comprises four distinct molecular variants, J. Clin. Oncol., 29, 1408, 10.1200/JCO.2009.27.4324

Robinson, 2012, Novel mutations target distinct subgroups of medulloblastoma, Nature, 488, 43, 10.1038/nature11213

Pugh, 2012, Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations, Nature, 488, 106, 10.1038/nature11329

Jones, 2012, Dissecting the genomic complexity underlying medulloblastoma, Nature, 488, 100, 10.1038/nature11284

Lin, 2016, Active medulloblastoma enhancers reveal subgroup-specific cellular origins, Nature, 530, 57, 10.1038/nature16546

Swartling, 2012, Distinct neural stem cell populations give rise to disparate brain tumors in response to N-MYC, Cancer Cell, 21, 601, 10.1016/j.ccr.2012.04.012

Kawauchi, 2012, A mouse model of the most aggressive subgroup of human medulloblastoma, Cancer Cell, 21, 168, 10.1016/j.ccr.2011.12.023

Wu, 2012, Clonal selection drives genetic divergence of metastatic medulloblastoma, Nature, 482, 529, 10.1038/nature10825

Hill, 2015, Combined MYC and p53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease, Cancer Cell, 27, 72, 10.1016/j.ccell.2014.11.002

Morrissy, 2016, Divergent clonal selection dominates medulloblastoma at recurrence, Nature, 529, 351, 10.1038/nature16478

Brodeur, 1984, Amplification of N-MYC in untreated human neuroblastomas correlates with advanced disease stage, Science, 224, 1121, 10.1126/science.6719137

Schleiermacher, 2009, Overall genomic pattern is a predictor of outcome in neuroblastoma, J. Clin. Oncol., 27, 1026, 10.1200/JCO.2008.16.0630

Westermann, 2008, Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas, Genome Biol., 9, R150, 10.1186/gb-2008-9-10-r150

Pugh, 2013, The genetic landscape of high-risk neuroblastoma, Nat. Genet., 45, 279, 10.1038/ng.2529

Molenaar, 2012, Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes, Nature, 483, 589, 10.1038/nature10910

Peifer, 2015, Telomerase activation by genomic rearrangements in high-risk neuroblastoma, Nature, 526, 700, 10.1038/nature14980

Blackwood, 1991, MAX: A helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with MYC, Science, 251, 1211, 10.1126/science.2006410

Ribon, 1994, C-MYC does not require MAX for transcriptional activity in PC-12 cells, Mol. Cell. Neurosci., 5, 277, 10.1006/mcne.1994.1032

Hopewell, 1995, The nerve growth factor-responsive PC12 cell line does not express the MYC dimerization partner MAX, Mol. Cell. Biol., 15, 3470, 10.1128/MCB.15.7.3470

Schiavi, 2011, Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma, Nat. Genet., 43, 663, 10.1038/ng.861

Fishbein, 2017, Comprehensive molecular characterization of pheochromocytoma and paraganglioma, Cancer Cell, 31, 181, 10.1016/j.ccell.2017.01.001

Romero, 2014, MAX inactivation in small cell lung cancer disrupts MYC-SWI/SNF programs and is synthetic lethal with BRG1, Cancer Discov., 4, 292, 10.1158/2159-8290.CD-13-0799

Kamoun, 2016, Integrated multi-omics analysis of oligodendroglial tumours identifies three subgroups of 1p/19q co-deleted gliomas, Nat. Commun., 7, 11263, 10.1038/ncomms11263

Turner, 2017, Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity, Nature, 543, 122, 10.1038/nature21356

Escot, 1986, Genetic alteration of the c-MYC protooncogene (MYC) in human primary breast carcinomas, Proc. Natl. Acad. Sci. USA, 83, 4834, 10.1073/pnas.83.13.4834

Escot, 1988, In situ c-MYC expression and genomic status of the c-MYC locus in infiltrating ductal carcinomas of the breast, Cancer Res., 48, 199

Slavc, 1990, MYC gene amplification and expression in primary human neuroblastoma, Cancer Res., 50, 1459

Weng, 2006, C-MYC is an important direct target of NOTCH1 in T-cell acute lymphoblastic leukemia/lymphoma, Genes Dev., 20, 2096, 10.1101/gad.1450406

Sears, 2000, Multiple RAS-dependent phosphorylation pathways regulate MYC protein stability, Genes Dev., 14, 2501, 10.1101/gad.836800

Tseng, 2014, PVT1 dependence in cancer with MYC copy-number increase, Nature, 512, 82, 10.1038/nature13311

Ulz, 2016, Co-occurrence of MYC amplification and TP53 mutations in human cancer, Nat. Genet., 48, 104, 10.1038/ng.3468

Pascale, 1996, C-MYC amplification in pre-malignant and malignant lesions induced in rat liver by the resistant hepatocyte model, Int. J. Cancer, 68, 136, 10.1002/(SICI)1097-0215(19960927)68:1<136::AID-IJC24>3.0.CO;2-8

Murphy, 2008, Distinct thresholds govern MYC’s biological output in vivo, Cancer Cell, 14, 447, 10.1016/j.ccr.2008.10.018

Fernandez, 2003, Genomic targets of the human c-MYC protein, Genes Dev., 17, 1115, 10.1101/gad.1067003

Kim, J., Lee, J.H., and Iyer, V.R. (2008). Global identification of MYC target genes reveals its direct role in mitochondrial biogenesis and its E-box usage in vivo. PLoS ONE, 3.

Shim, 1997, MYC target genes in neoplastic transformation, Curr. Top. Microbiol. Immunol., 224, 181

Dang, 1999, C-MYC target genes involved in cell growth, apoptosis, and metabolism, Mol. Cell. Biol., 19, 1, 10.1128/MCB.19.1.1

Molyneux, 2012, Burkitt’s lymphoma, Lancet, 379, 1234, 10.1016/S0140-6736(11)61177-X

Bregni, 1982, Human c-MYC onc gene is located on the region of chromosome 8 that is translocated in burkitt lymphoma cells, Proc. Natl. Acad. Sci. USA, 79, 7824, 10.1073/pnas.79.24.7824

Epstein, 1977, Chromosome 14 translocation in african and north american burkitt’s lymphoma, Int. J. Cancer, 19, 482, 10.1002/ijc.2910190408

Taub, 1982, Translocation of the c-MYC gene into the immunoglobulin heavy chain locus in human burkitt lymphoma and murine plasmacytoma cells, Proc. Natl. Acad. Sci. USA, 79, 7837, 10.1073/pnas.79.24.7837

Marcu, 1983, Transcriptionally active c-MYC oncogene is contained within NIARD, a DNA sequence associated with chromosome translocations in B-cell neoplasia, Proc. Natl. Acad. Sci. USA, 80, 519, 10.1073/pnas.80.2.519

Chng, 2011, Clinical and biological implications of MYC activation: A common difference between MGUS and newly diagnosed multiple myeloma, Leukemia, 25, 1026, 10.1038/leu.2011.53

Mitsiades, 2004, Focus on multiple myeloma, Cancer Cell, 6, 439, 10.1016/j.ccr.2004.10.020

Stewart, 2005, Prognostic and therapeutic significance of myeloma genetics and gene expression profiling, J. Clin. Oncol., 23, 6339, 10.1200/JCO.2005.05.023

Singhal, 2006, Multiple myeloma, Clin. J. Am. Soc. Nephrol., 1, 1322, 10.2215/CJN.03060906

Dib, A., Gabrea, A., Glebov, O.K., Bergsagel, P.L., and Kuehl, W.M. (2008). Characterization of MYC translocations in multiple myeloma cell lines. J. Natl. Cancer Inst. Monogr., 25–31.

Jimenez, 2017, A next-generation sequencing strategy for evaluating the most common genetic abnormalities in multiple myeloma, J. Mol. Diagn., 19, 99, 10.1016/j.jmoldx.2016.08.004

Grisanzio, 2010, Chromosome 8q24-associated cancers and MYC, Genes Cancer, 1, 555, 10.1177/1947601910381380

Easton, 2008, Genome-wide association studies in cancer, Hum. Mol. Genet., 17, R109, 10.1093/hmg/ddn287

Zhang, 2016, Identification of focally amplified lineage-specific super-enhancers in human epithelial cancers, Nat. Genet., 48, 176, 10.1038/ng.3470

Stone, 2015, DNA methylation of oestrogen-regulated enhancers defines endocrine sensitivity in breast cancer, Nat. Commun., 6, 7758, 10.1038/ncomms8758

Heyn, 2016, Epigenomic analysis detects aberrant super-enhancer DNA methylation in human cancer, Genome Biol., 17, 11, 10.1186/s13059-016-0879-2

Corradin, 2014, Enhancer variants: Evaluating functions in common disease, Genome Med., 6, 85, 10.1186/s13073-014-0085-3

Wright, 2010, Upregulation of c-MYC in cis through a large chromatin loop linked to a cancer risk-associated single-nucleotide polymorphism in colorectal cancer cells, Mol. Cell. Biol., 30, 1411, 10.1128/MCB.01384-09

Ahmadiyeh, 2010, 8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range interaction with MYC, Proc. Natl. Acad. Sci. USA, 107, 9742, 10.1073/pnas.0910668107

Haiman, 2007, Multiple regions within 8q24 independently affect risk for prostate cancer, Nat. Genet., 39, 638, 10.1038/ng2015

Wasserman, 2010, An 8q24 gene desert variant associated with prostate cancer risk confers differential in vivo activity to a MYC enhancer, Genome Res., 20, 1191, 10.1101/gr.105361.110

Oktay, 2016, IDH-mutant glioma specific association of rs55705857 located at 8q24.21 involves MYC deregulation, Sci. Rep., 6, 27569, 10.1038/srep27569

Tomlinson, 2008, A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3, Nat. Genet., 40, 623, 10.1038/ng.111

Haiman, 2007, A common genetic risk factor for colorectal and prostate cancer, Nat. Genet., 39, 954, 10.1038/ng2098

Pomerantz, 2009, The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer, Nat. Genet., 41, 882, 10.1038/ng.403

Tuupanen, 2009, The common colorectal cancer predisposition SNP rs6983267 at chromosome 8q24 confers potential to enhanced WNT signaling, Nat. Genet., 41, 885, 10.1038/ng.406

Sur, 2016, The role of enhancers in cancer, Nat. Rev. Cancer, 16, 483, 10.1038/nrc.2016.62

Shi, 2013, Role of SWI/SNF in acute leukemia maintenance and enhancer-mediated MYC regulation, Genes Dev., 27, 2648, 10.1101/gad.232710.113

Pinz, S., Unser, S., and Rascle, A. (2016). Signal transducer and activator of transcription STAT5 is recruited to c-MYC super-enhancer. BMC Mol. Biol., 17.

Radtke, 2009, Genomic analysis reveals few genetic alterations in pediatric acute myeloid leukemia, Proc. Natl. Acad. Sci. USA, 106, 12944, 10.1073/pnas.0903142106

Kuhn, 2012, High-resolution genomic profiling of adult and pediatric core-binding factor acute myeloid leukemia reveals new recurrent genomic alterations, Blood, 119, e67, 10.1182/blood-2011-09-380444

Hnisz, 2013, Super-enhancers in the control of cell identity and disease, Cell, 155, 934, 10.1016/j.cell.2013.09.053

Rennoll, 2015, Regulation of MYC gene expression by aberrant WNT/β-catenin signaling in colorectal cancer, World J. Biol. Chem., 6, 290, 10.4331/wjbc.v6.i4.290

Yochum, G.S. (2011). Multiple WNT/β-catenin responsive enhancers align with the MYC promoter through long-range chromatin loops. PLoS ONE, 6.

Herranz, 2014, A NOTCH1-driven MYC enhancer promotes T cell development, transformation and acute lymphoblastic leukemia, Nat. Med., 20, 1130, 10.1038/nm.3665

Ryan, 2015, Detection of enhancer-associated rearrangements reveals mechanisms of oncogene dysregulation in B-cell lymphoma, Cancer Discov., 5, 1058, 10.1158/2159-8290.CD-15-0370

Affer, 2014, Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma, Leukemia, 28, 1725, 10.1038/leu.2014.70

Delmore, 2011, Bet bromodomain inhibition as a therapeutic strategy to target c-MYC, Cell, 146, 904, 10.1016/j.cell.2011.08.017

Gregory, 2003, Phosphorylation by glycogen synthase kinase-3 controls c-MYC proteolysis and subnuclear localization, J. Biol. Chem., 278, 51606, 10.1074/jbc.M310722200

Yeh, 2004, A signalling pathway controlling c-MYC degradation that impacts oncogenic transformation of human cells, Nat. Cell Biol., 6, 308, 10.1038/ncb1110

Popov, 2007, The ubiquitin-specific protease USP28 is required for MYC stability, Nat. Cell Biol., 9, 765, 10.1038/ncb1601

Pan, 2015, USP37 directly deubiquitinates and stabilizes c-MYC in lung cancer, Oncogene, 34, 3957, 10.1038/onc.2014.327

Kim, D., Hong, A., Park, H.I., Shin, W.H., Yoo, L., Jeon, S.J., and Chung, K.C. (2017). Deubiquitinating enzyme USP22 positively regulates c-MYC stability and tumorigenic activity in mammalian and breast cancer cells. J. Cell. Physiol.

Diefenbacher, 2014, The deubiquitinase USP28 controls intestinal homeostasis and promotes colorectal cancer, J. Clin. Investig., 124, 3407, 10.1172/JCI73733

Akhoondi, 2007, FBXW7/hCDC4 is a general tumor suppressor in human cancer, Cancer Res., 67, 9006, 10.1158/0008-5472.CAN-07-1320

Sun, 2015, The nucleolar ubiquitin-specific protease USP36 deubiquitinates and stabilizes c-MYC, Proc. Natl. Acad. Sci. USA, 112, 3734, 10.1073/pnas.1411713112

Welcker, 2004, A nucleolar isoform of the FBW7 ubiquitin ligase regulates c-MYC and cell size, Curr. Biol., 14, 1852, 10.1016/j.cub.2004.09.083

Kim, 2003, SKP2 regulates MYC protein stability and activity, Mol. Cell, 11, 1177, 10.1016/S1097-2765(03)00173-4

Kimura, 2007, MM-1 facilitates degradation of c-MYC by recruiting proteasome and a novel ubiquitin E3 ligase, Int. J. Oncol., 31, 829

Johansson, 2003, Implication of the ubiquitin/proteasome system in MYC-regulated transcription, Cell Cycle, 2, 403

Gstaiger, 2001, SKP2 is oncogenic and overexpressed in human cancers, Proc. Natl. Acad. Sci. USA, 98, 5043, 10.1073/pnas.081474898

Cowling, 2014, Burkitt’s lymphoma-associated c-MYC mutations converge on a dramatically altered target gene response and implicate NOL5A/NOP56 in oncogenesis, Oncogene, 33, 3519, 10.1038/onc.2013.338

Bonilla, 2016, Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma, Nat. Genet., 48, 398, 10.1038/ng.3525

Bhatia, 1993, Point mutations in the c-MYC transactivation domain are common in burkitt’s lymphoma and mouse plasmacytomas, Nat. Genet., 5, 56, 10.1038/ng0993-56

Love, 2012, The genetic landscape of mutations in burkitt lymphoma, Nat. Genet., 44, 1321, 10.1038/ng.2468

Schmitz, 2012, Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics, Nature, 490, 116, 10.1038/nature11378

Richter, 2012, Recurrent mutation of the ID3 gene in burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing, Nat. Genet., 44, 1316, 10.1038/ng.2469

Bahram, 2000, c-MYC hot spot mutations in lymphomas result in inefficient ubiquitination and decreased proteasome-mediated turnover, Blood, 95, 2104, 10.1182/blood.V95.6.2104

Symonds, 1989, Transformation of murine myelomonocytic cells by MYC: Point mutations in v-MYC contribute synergistically to transforming potential, Oncogene, 4, 285

Hemann, 2005, Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants, Nature, 436, 807, 10.1038/nature03845

Chang, 2000, The c-MYC transactivation domain is a direct modulator of apoptotic versus proliferative signals, Mol. Cell. Biol., 20, 4309, 10.1128/MCB.20.12.4309-4319.2000

Chakraborty, 2015, A common functional consequence of tumor-derived mutations within c-MYC, Oncogene, 34, 2406, 10.1038/onc.2014.186

Richards, 2016, Structural basis of N-MYC binding by Aurora-A and its destabilization by kinase inhibitors, Proc. Natl. Acad. Sci. USA, 113, 13726, 10.1073/pnas.1610626113

Kandoth, 2013, Mutational landscape and significance across 12 major cancer types, Nature, 502, 333, 10.1038/nature12634

Stokoe, 1997, Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B, Science, 277, 567, 10.1126/science.277.5325.567

Maehama, 1998, The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate, J. Biol. Chem., 273, 13375, 10.1074/jbc.273.22.13375

Myers, 1998, The lipid phosphatase activity of pten is critical for its tumor supressor function, Proc. Natl. Acad. Sci. USA, 95, 13513, 10.1073/pnas.95.23.13513

Osaki, 2004, Pi3k-akt pathway: Its functions and alterations in human cancer, Apoptosis, 9, 667, 10.1023/B:APPT.0000045801.15585.dd

Cross, 1995, Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B, Nature, 378, 785, 10.1038/378785a0

Zhao, 2008, Helical domain and kinase domain mutations in p110α of phosphatidylinositol 3-kinase induce gain of function by different mechanisms, Proc. Natl. Acad. Sci. USA, 105, 2652, 10.1073/pnas.0712169105

Li, 1997, PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer, Science, 275, 1943, 10.1126/science.275.5308.1943

Stambolic, 1998, Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN, Cell, 95, 29, 10.1016/S0092-8674(00)81780-8

Chardin, 1993, Human SOS1: A guanine nucleotide exchange factor for ras that binds to GRB2, Science, 260, 1338, 10.1126/science.8493579

Roberts, 2007, Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer, Oncogene, 26, 3291, 10.1038/sj.onc.1210422

Hayes, 2016, Long-term ERK inhibition in KRAS-mutant pancreatic cancer is associated with MYC degradation and senescence-like growth suppression, Cancer Cell, 29, 75, 10.1016/j.ccell.2015.11.011

Suire, 2002, Activation of phosphoinositide 3-kinase gamma by RAS, Curr. Biol., 12, 1068, 10.1016/S0960-9822(02)00933-8

Warne, 1994, Phosphatidylinositol-3-OH kinase as a direct target of RAS, Nature, 370, 527, 10.1038/370527a0

Kodaki, 1994, The activation of phosphatidylinositol 3-kinase by RAS, Curr. Biol., 4, 798, 10.1016/S0960-9822(00)00177-9

Rottmann, 2006, The mad side of the MAX network: Antagonizing the function of MYC and more, Curr. Top. Microbiol. Immunol., 302, 63

Ayer, 1993, Mad: A heterodimeric partner for MAX that antagonizes MYC transcriptional activity, Cell, 72, 211, 10.1016/0092-8674(93)90661-9

Zhu, 2008, Activation of PI3K/AKT and MAPK pathways regulates MYC-mediated transcription by phosphorylating and promoting the degradation of MAD1, Proc. Natl. Acad. Sci. USA, 105, 6584, 10.1073/pnas.0802785105

Prior, 2012, A comprehensive survey of RAS mutations in cancer, Cancer Res., 72, 2457, 10.1158/0008-5472.CAN-11-2612

Gibbs, 1988, Purification of RAS GTPase activating protein from bovine brain, Proc. Natl. Acad. Sci. USA, 85, 5026, 10.1073/pnas.85.14.5026

Vogel, 1988, Cloning of bovine GAP and its interaction with oncogenic RAS p21, Nature, 335, 90, 10.1038/335090a0

Franken, 1993, Three-dimensional structures and properties of a transforming and a nontransforming glycine-12 mutant of p21H-RAS, Biochemistry, 32, 8411, 10.1021/bi00084a005

Gremer, 2008, Fluoride complexes of oncogenic RAS mutants to study the RAS-RASGAP interaction, Biol. Chem., 389, 1163, 10.1515/BC.2008.132

Davies, 2002, Mutations of the braf gene in human cancer, Nature, 417, 949, 10.1038/nature00766

Rizzo, 2016, BRAF and MEK inhibitors in pediatric glioma: New therapeutic strategies, new toxicities, Expert Opin. Drug Metab. Toxicol., 12, 1397, 10.1080/17425255.2016.1214710

Bartram, 1983, Translocation of c-ab1 oncogene correlates with the presence of a philadelphia chromosome in chronic myelocytic leukaemia, Nature, 306, 277, 10.1038/306277a0

Sawyers, 1992, Dominant negative MYC blocks transformation by ABL oncogenes, Cell, 70, 901, 10.1016/0092-8674(92)90241-4

Ratajczak, 1994, The role of c-MYC protooncogene in chronic myelogenous leukemia, Folia Histochem. Cytobiol., 32, 231

Miyamoto, 2001, The JAK2 inhibitor AG490 predominantly abrogates the growth of human B-precursor leukemic cells with 11q23 translocation or philadelphia chromosome, Leukemia, 15, 1758, 10.1038/sj.leu.2402260

Ariyoshi, 2000, Constitutive activation of STAT5 by a point mutation in the SH2 domain, J. Biol. Chem., 275, 24407, 10.1074/jbc.M909771199

Oliver, 2012, BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia, Nat. Chem. Biol., 8, 285, 10.1038/nchembio.775

Lord, 2000, The IL-2 receptor promotes lymphocyte proliferation and induction of the c-MYC, Bcl-2, and Bcl-x genes through the trans-activation domain of STAT5, J. Immunol., 164, 2533, 10.4049/jimmunol.164.5.2533

Nosaka, 1999, STAT5 as a molecular regulator of proliferation, differentiation and apoptosis in hematopoietic cells, EMBO J., 18, 4754, 10.1093/emboj/18.17.4754

Beth, 2008, In vivo identification of novel STAT5 target genes, Nucleic Acids Res., 36, 3802, 10.1093/nar/gkn271

Pinz, 2015, Deacetylase inhibitors repress STAT5-mediated transcription by interfering with bromodomain and extra-terminal (bet) protein function, Nucleic Acids Res., 43, 3524, 10.1093/nar/gkv188

Kralovics, 2008, Genetic complexity of myeloproliferative neoplasms, Leukemia, 22, 1841, 10.1038/leu.2008.233

James, 2005, A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera, Nature, 434, 1144, 10.1038/nature03546

Hassan, 2015, Coexistence of JAK2 and BCR-ABL mutation in patient with myeloproliferative neoplasm, Niger. Med. J., 56, 74, 10.4103/0300-1652.149177

Pahore, 2011, JAK2V617F mutation in chronic myeloid leukemia predicts early disease progression, J. Coll. Phys. Surg. Pak., 21, 472

Dubik, 1987, Stimulation of c-MYC oncogene expression associated with estrogen-induced proliferation of human breast cancer cells, Cancer Res., 47, 6517

Dubik, 1992, Mechanism of estrogen activation of c-MYC oncogene expression, Oncogene, 7, 1587

Carroll, 2006, Genome-wide analysis of estrogen receptor binding sites, Nat. Genet., 38, 1289, 10.1038/ng1901

Butt, 2008, Cell cycle machinery: Links with genesis and treatment of breast cancer, Adv. Exp. Med. Biol., 630, 189, 10.1007/978-0-387-78818-0_12

Alles, M.C., Margaret, G.-G., David, J.N., Yixin, W., John, A.F., Robert, L.S., Elizabeth, A.M., and Christopher, J.O. (2009). Meta-analysis and gene set enrichment relative to er status reveal elevated activity of MYC and E2F in the “basal” breast cancer subgroup. PLoS ONE, 4.

Musgrove, E.A., Sergio, C.M., Loi, S., Inman, C.K., Anderson, L.R., Alles, M.C., Pinese, M., Caldon, C.E., Schütte, J., and Gardiner-Garden, M. (2008). Identification of functional networks of estrogen- and c-MYC-responsive genes and their relationship to response to tamoxifen therapy in breast cancer. PLoS ONE, 3.

Chandriani, S., Frengen, E., Cowling, V.H., Pendergrass, S.A., Perou, C.M., Whitfield, M.L., and Cole, M.D. (2009). A core MYC gene expression signature is prominent in basal-like breast cancer but only partially overlaps the core serum response. PLoS ONE, 4.

Tanaka, 1999, Centrosomal kinase AIK1 is overexpressed in invasive ductal carcinoma of the breast, Cancer Res., 59, 2041

Zheng, 2016, Nuclear aurka acquires kinase-independent transactivating function to enhance breast cancer stem cell phenotype, Nat. Commun., 7, 10180, 10.1038/ncomms10180

Zhou, 1998, Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation, Nat. Genet., 20, 189, 10.1038/2496

Frederick, 2004, Transforming growth factor β-mediated transcriptional repression of c-myc is dependent on direct binding of Smad3 to a novel repressive Smad binding element, Mol. Cell. Biol., 24, 2546, 10.1128/MCB.24.6.2546-2559.2004

Yagi, 2001, C-MYC is a downstream target of the SMAD pathway, J. Biol. Chem., 277, 854, 10.1074/jbc.M104170200

Jeruss, 2003, Down-regulation of activin, activin receptors, and SMADS in high-grade breast cancer, Cancer Res., 63, 3783

Sekimoto, 2007, Reversible SMAD-dependent signaling between tumor suppression and oncogenesis, Cancer Res., 67, 5090, 10.1158/0008-5472.CAN-06-4629

Chen, 2001, Defective repression of c-MYC in breast cancer cells: A loss at the core of the transforming growth factor beta growth arrest program, Proc. Natl. Acad. Sci. USA, 98, 992, 10.1073/pnas.98.3.992

Shi, 2017, Research of the relationship between β-catenin and c-myc-mediated Wnt pathway and laterally spreading tumors occurrence, Eur. Rev. Med. Pharmacol. Sci., 21, 252

Zhan, 2017, WNT signaling in cancer, Oncogene, 36, 1461, 10.1038/onc.2016.304

Myant, 2011, WNT/MYC interactions in intestinal cancer: Partners in crime, Exp. Cell Res., 317, 2725, 10.1016/j.yexcr.2011.08.001

Najdi, 2011, WNT signaling and colon carcinogenesis: Beyond APC, J. Carcinog., 10, 5, 10.4103/1477-3163.78111

Morin, 1997, Activation of β-catenin-Tcf signaling in colon cancer by mutations in β-catenin or APC, Science, 275, 1787, 10.1126/science.275.5307.1787

Liu, 2000, Mutations in AXIN2 cause colorectal cancer with defective mismatch repair by activating β-catenin/TCF signalling, Nat. Genet., 26, 146, 10.1038/79859

Mazzoni, 2014, AXIN1 and AXIN2 variants in gastrointestinal cancers, Cancer Lett., 355, 1, 10.1016/j.canlet.2014.09.018

Schlaeger, 2008, Etiology-dependent molecular mechanisms in human hepatocarcinogenesis, Hepatology, 47, 511, 10.1002/hep.22033

Nesbit, 1999, MYC oncogenes and human neoplastic disease, Oncogene, 18, 3004, 10.1038/sj.onc.1202746

Dolezal, J.M., Wang, H., Kulkarni, S., Jackson, L., Lu, J., Ranganathan, S., Goetzman, E.S., Bharathi, S., Beezhold, K., and Byersdorfer, C.A. (2017). Sequential adaptive changes in a c-MYC-driven model of hepatocellular carcinoma. J. Biol. Chem.

Aretz, 2006, Should children at risk for familial adenomatous polyposis be screened for hepatoblastoma and children with apparently sporadic hepatoblastoma be screened for APC germline mutations?, Pediatr. Blood Cancer, 47, 811, 10.1002/pbc.20698

Cairo, 2008, Hepatic stem-like phenotype and interplay of WNT/β-catenin and MYC signaling in aggressive childhood liver cancer, Cancer Cell, 14, 471, 10.1016/j.ccr.2008.11.002

Wang, 2016, Coordinated activities of multiple MYC-dependent and MYC-independent biosynthetic pathways in hepatoblastoma, J. Biol. Chem., 291, 26241, 10.1074/jbc.M116.754218

Kan, 2013, Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma, Genome Res., 23, 1422, 10.1101/gr.154492.113

Ding, X., Yang, Y., Han, B., Du, C., Xu, N., Huang, H., Cai, T., Zhang, A., Han, Z.G., and Zhou, W. (2014). Transcriptomic characterization of hepatocellular carcinoma with CTNNB1 mutation. PLoS ONE, 9.

Ferrando, 2017, The NOTCH1-MYC highway towards T-cell acute lymphoblastic leukemia, Blood, 129, 1124, 10.1182/blood-2016-09-692582

Kopan, 2012, Notch signaling, Cold Spring Harb. Perspect. Biol., 4, a011213, 10.1101/cshperspect.a011213

Ellisen, 1991, TAN-1, the human homolog of the drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms, Cell, 66, 649, 10.1016/0092-8674(91)90111-B

Weng, 2004, Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia, Science, 306, 269, 10.1126/science.1102160

Grim, 2007, FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors, J. Exp. Med., 204, 1813, 10.1084/jem.20070876

Thompson, 2007, The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia, J. Exp. Med., 204, 1825, 10.1084/jem.20070872

King, 2013, The ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by regulating MYC stability, Cell, 153, 1552, 10.1016/j.cell.2013.05.041

Mertins, 2016, Proteogenomics connects somatic mutations to signalling in breast cancer, Nature, 534, 55, 10.1038/nature18003

Zhang, 2014, Proteogenomic characterization of human colon and rectal cancer, Nature, 513, 382, 10.1038/nature13438

Zhang, 2016, Integrated proteogenomic characterization of human high-grade serous ovarian cancer, Cell, 166, 755, 10.1016/j.cell.2016.05.069

Wasylishen, 2013, MYC phosphorylation at novel regulatory regions suppresses transforming activity, Cancer Res., 73, 6504, 10.1158/0008-5472.CAN-12-4063

Huang, 2004, Negative control of the MYC protein by the stress-responsive kinase PAK2, Mol. Cell. Biol., 24, 1582, 10.1128/MCB.24.4.1582-1594.2004

Pulverer, 1994, Site-specific modulation of c-MYC cotransformation by residues phosphorylated in vivo, Oncogene, 9, 59

Luscher, 1989, MYC oncoproteins are phosphorylated by casein kinase II, EMBO J, 8, 1111, 10.1002/j.1460-2075.1989.tb03481.x

Kalkat, M., Chan, P.K., Wasylishen, A.R., Srikumar, T., Kim, S.S., Ponzielli, R., Bazett-Jones, D.P., Raught, B., and Penn, L.Z. (2014). Identification of c-MYC sumoylation by mass spectrometry. PLoS ONE, 9.

Cuijpers, 2015, c-MYC is targeted to the proteasome for degradation in a sumoylation-dependent manner, regulated by PIAS1, SENP7 and RNF4, Cell Cycle, 14, 1859, 10.1080/15384101.2015.1040965

Sabo, A., Doni, M., and Amati, B. (2014). Sumoylation of MYC-family proteins. PLoS ONE, 9.

Zhang, 2005, Six lysine residues on c-MYC are direct substrates for acetylation by p300, Biochem. Biophys. Res. Commun., 336, 274, 10.1016/j.bbrc.2005.08.075

Faiola, 2005, Dual regulation of c-MYC by p300 via acetylation-dependent control of MYC protein turnover and coactivation of MYC-induced transcription, Mol. Cell. Biol., 25, 10220, 10.1128/MCB.25.23.10220-10234.2005

(2017, February 27). Phosphositeplus: Myc (human). Available online: http://www.phosphosite.org/proteinAction.action?id=947&showAllSites=true.

Fletcher, 2015, Small-molecule inhibitors of the MYC oncoprotein, Biochim. Biophys. Acta, 1849, 525, 10.1016/j.bbagrm.2014.03.005

Soucek, 2002, Omomyc, a potential MYC dominant negative, enhances MYC-induced apoptosis, Cancer Res., 62, 3507

Soucek, 2008, Modelling MYC inhibition as a cancer therapy, Nature, 455, 679, 10.1038/nature07260

Li, 2014, Inactivation of MYC reverses tumorigenesis, J. Intern. Med., 276, 52, 10.1111/joim.12237